Glow Stack
Protocol overview
Protocol details
Use the admin panel to add markdown content here with practical steps, caveats, and references.
Linked peptides
Peptides that appear in this protocol, with their primary perceived effect profiles.
Community tags (where this is used)
Lightweight, anonymous voting on where this protocol tends to show up in people's research (not recommendations or medical guidance).
Community stacks, dosing & cycles
Anonymous, research-framed suggestions for how people structure this protocol in practice. No medical advice; use as inspiration, then cross-check against primary evidence.
No community variants logged yet. The sample row below is illustrative until real submissions appear.
| Variant | Stack | Dosage | Cycle | Submitted | Upvotes |
|---|---|---|---|---|---|
Sample: 8-week tendon stack (example) Illustrative structure only. Replace with real-world, research-framed variants once community submissions are available. | BPC-157 + TB-500 + progressive PT 3x/week; sleep and protein focus | e.g. BPC-157 ~250 mcg daily, TB-500 twice weekly | 8–12 weeks, then reassess / deload | — | — |
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.PubMedTB-500 (Thymosin Beta-4)
Drug testing and analysis · 2012
Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.PubMedTB-500 (Thymosin Beta-4)
Journal of chromatography. A · 2012
Copper Complexes with New Glycyl-l-histidyl-l-lysine-Hyaluronan Conjugates Show Antioxidant Properties and Osteogenic and Angiogenic Synergistic Effects.PubMedGHK-Cu
Bioconjugate chemistry · 2025
Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms.PubMedGHK-Cu
Frontiers in pharmacology · 2025
An injectable hydroxyapatite microsphere filler loaded with GHK-Cu tripeptide for anti-Inflammatory and antioxidant.PubMedGHK-Cu
Colloids and surfaces. B, Biointerfaces · 2025
Current reviews in musculoskeletal medicine · 2025
BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185.PubMedBPC-157
Pharmaceuticals (Basel, Switzerland) · 2025
Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on "Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185".PubMedBPC-157
Pharmaceuticals (Basel, Switzerland) · 2025